Monogram studies show effectiveness of Trofile co-receptor tropism assays in HIV treatment

By Lisa Kerner

Charlotte, N.C., Aug. 14 - Monogram Biosciences, Inc. said four studies of its Trofile co-receptor tropism assay suggest the need for phenotypic assays in evaluating specific cellular co-receptors (either CCR5 or CXCR4) that individual strains of HIV use to gain access to host cells.

Analyzing tropism helps determine whether new drugs targeting CCR5 antagonists will be effective in individual HIV-infected patients, according to a company news release.

"These data suggest that the Trofile co-receptor tropism assay is an effective method of identifying appropriate patients for treatment with CCR5 antagonists," chief scientific offer Chris Petropoulos said in the release.

"By virtue of its high positive and negative predictive values, the Trofile assay is highly capable of insuring that individuals receive treatments that are most likely to provide them with clinical benefit."

Two of the studies were conducted by Monogram, one by Pfizer, Inc. and one by the AIDS Clinical Trial Group 5211 study team and Schering Plough Corp.

The company will present the study results at the XVI International AIDS Conference in Toronto.

Monogram, located in South San Francisco, Calif., develops products to treat serious infectious diseases and cancer.

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.